Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults (MOT089)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00474279
Recruitment Status : Completed
First Posted : May 16, 2007
Last Update Posted : May 16, 2007
Information provided by:
University of Virginia

Brief Summary:
The purpose of this study is to determine whether treatment of healthy older men and women with oral MK-677 for 12 months will enhance pulsatile GH release and increase mean GH and IGF-I concentrations into the range of young adults and will have favorable effects on body composition and functional ability on older adults.

Condition or disease Intervention/treatment Phase
Aging Drug: Orally active growth hormone secretagogue (MK-677) Phase 1 Phase 2

Detailed Description:
This is a two year, double-blind, placebo-controlled cross-over trial of once daily administration of MK-677, an oral GH secretagogue, to healthy older adults. During the first year, subjects will be randomized to MK-677 or placebo treatment. In each of three subgroups of subjects (men, women off and women on hormone replacement therapy), 16 subjects will receive MK-677 and 8 will receive placebo. After 1 year, the subjects who received placebo will be switched to MK-677 treatment; the subjects who received MK-677 for the first year will be randomized to either placebo or MK-677 for the second year of the study.The study will test changes in GH, IGF-I, body composition and function.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults
Study Start Date : July 1998
Actual Study Completion Date : June 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Primary Outcome Measures :
  1. At 12 months: 24-hour mean growth hormone concentrations
  2. Insulin-like growth factor-I concentrations
  3. Body weight and fat mass, specifically abdominal visceral fat
  4. Fat-free mass
  5. Safety determined by routine laboratory tests at 1 to 3 month intervals, yearly pap smears and mammograms

Secondary Outcome Measures :
  1. at 12 months: Growth hormone secretory dynamics
  2. Isokinetic muscle strength (knee and shoulder)
  3. Thigh muscle cross-sectional area
  4. Function tests (timed walks, stair climb, chair rise)
  5. Quality of life assessments
  6. Insulin sensitivity
  7. Lipid profile
  8. Resting metabolic rate
  9. Aerobic exercise capacity
  10. Exploratory outcomes:
  11. effects of gender and HRT on primary outcomes
  12. effects of treatment in year 2: Year 2 outcomes include effects of continuation on MK-677, or crossover to placebo, placebo to MK-677
  13. bone mineral density at end of year 2.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy men and women  60 years of age, with a body mass index of < 35 kg/m2.

Exclusion Criteria:

  • Medication known to affect GH secretion, other than estrogen replacement therapy
  • Coronary artery disease,
  • Congestive heart failure,
  • Peripheral vascular disease,
  • Diabetes mellitus (requiring insulin or an oral hypoglycemic agent),
  • Significant hypertension (BP >180 systolic or >100 diastolic at rest);
  • Renal, hepatic, pulmonary disease;
  • Untreated hypothyroidism, untreated hyperthyroidism;
  • History of seizure disorder;
  • History of malignancy (other than some skin cancers), history of active chronic infections (e.g., HIV, tuberculosis).
  • Hematocrit < 40%, men, < 36%, women
  • History of daily tobacco use within past 3 months
  • Chronic alcohol abuse
  • Strenuous exercise for average of more than 60 min/day
  • Investigational drug within past 6 weeks
  • Psychiatric history, especially anorexia nervosa
  • Transmeridian travel within 2 weeks prior to or during study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00474279

Layout table for location information
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
Layout table for investigator information
Principal Investigator: Michael O. Thorner, MBBS, DSc, University of Virginia
Layout table for additonal information Identifier: NCT00474279    
Other Study ID Numbers: HIC #7444
NIH RO1 DK32632
First Posted: May 16, 2007    Key Record Dates
Last Update Posted: May 16, 2007
Last Verified: May 2007
Keywords provided by University of Virginia:
Growth hormone secretagogue
Body composition
Functional ability
Additional relevant MeSH terms:
Layout table for MeSH terms
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs